Júlio Antônio, Clinical Oncologist at São Paulo State Cancer Institute (ICESP), shared a post on LinkedIn:
“Closing out the year at the San Antonio Breast Cancer Symposium (SABCS 2025) is always special.
I was pleased to present a collaboratively developed work that uses artificial intelligence applied to breast cancer to support therapeutic decisions in a more personalized and cost-effective way.
Our AI model was able to identify patients with a higher likelihood of benefit from chemotherapy (25%) and those with a low likelihood of benefit (50%), which can reduce the need for genomic testing in about 75% of cases. The remaining 25%, of intermediate risk still requires Oncotype DX.
In addition, the model identified patients at high risk of recurrence even with a Recurrence Score ≤ 25.
This is a relevant step in the development of solutions that expand access to precision medicine, especially in low-income countries and in health systems with limited resources.
My thanks to all the co-authors and collaborators involved.”
More posts featuring SABCS 2025.